| Název: | Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report |
| Autoři: | Ostašov, Pavel null, null Robertson, Henry Piazza, Paolo Datta, Avik Apperley, Jane Houdová, Lucie Lysák, Daniel Holubová, Monika Tesařová, Kateřina Caputo, Valentina S. Barozzi, Iros |
| Citace zdrojového dokumentu: | OSTAŠOV, P. ROBERTSON, H. PIAZZA, P. DATTA, A. APPERLEY, J. HOUDOVÁ, L. LYSÁK, D. HOLUBOVÁ, M. TESAŘOVÁ, K. CAPUTO, VS. BAROZZI, I.Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. Frontiers in Oncology, 2020, roč. 10, č. OCT 2020, s. 1-9 (article 584607). ISSN 2234-943X. |
| Datum vydání: | 2020 |
| Nakladatel: | Frontiers Media |
| Typ dokumentu: | článek article |
| URI: | 2-s2.0-85096052038 http://hdl.handle.net/11025/42923 |
| ISSN: | 2234-943X |
| Klíčová slova v dalším jazyce: | chronic lymphoid leukemia (CLL);single-cell RNA-seq (scRNA-seq);therapy resistance;disease progression;advanced disease;case report |
| Abstrakt v dalším jazyce: | Genetic and transcriptional heterogeneity of Chronic lymphocytic leukaemia (CLL) limits prevention of disease progression. Longitudinal single-cell transcriptomics represents the state-of-the-art method to profile the disease heterogeneity at diagnosis and to inform about disease evolution. Here, we apply single-cell RNA-seq to a CLL case, sampled at diagnosis and relapse, that was treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) and underwent a dramatic decrease in CD19 expression during disease progression. Computational analyses revealed a major switch in clones’ dominance during treatment. The clone that expanded at relapse showed 17p and 3p chromosomal deletions, and up-regulation of pathways related to motility, cytokine signaling and antigen presentation. Single-cell RNA-seq uniquely revealed that this clone was already present at low frequency at diagnosis, and it displays feature of plasma cell differentiation, consistent with a more aggressive phenotype. This study shows the benefit of single-cell profiling of CLL heterogeneity at diagnosis, to identify clones that might otherwise not be recognized and to determine the best treatment options. |
| Práva: | © Frontiers Media |
| Vyskytuje se v kolekcích: | Články / Articles (NTIS) OBD |
Soubory připojené k záznamu:
| Soubor | Velikost | Formát | |
|---|---|---|---|
| Frontier2020_Ostasov_Evolution_of_Advanced.pdf | 2,19 MB | Adobe PDF | Zobrazit/otevřít |
Použijte tento identifikátor k citaci nebo jako odkaz na tento záznam:
http://hdl.handle.net/11025/42923Všechny záznamy v DSpace jsou chráněny autorskými právy, všechna práva vyhrazena.